Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 2.850
-0.010 (-0.35%)
Sep 22, 2026, 5:24 PM CET
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 300.72 million as of September 22, 2026. Its market cap has increased by 407.12% in one year.
Market Cap
300.72M
Enterprise Value
207.46M
Revenue
139.36M
Ranking
n/a
PE Ratio
4.03
Stock Price
2.85
ChartMarket Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 300.72M, an increase of 381.19%. That is a compound annual growth rate of 14.14%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 22, 2026 | 300.72M | 93.88% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| FluoGuide | 572.23M |
| Xspray Pharma AB | 442.87M |
| Mendus AB | 428.39M |
| Cantargia AB | 390.07M |
| Corline Biomedical AB | 371.09M |
| Intervacc AB | 344.22M |
| IRLAB Therapeutics AB | 256.68M |
| Isofol Medical AB | 237.16M |